Valitor Announces Presentation on Novel Anti-VEGF Antibody Conjugate and Multivalent Polymer Technology Platform at Upcoming Ophthalmology Innovation Source (OIS) Summit

– Preclinical data support twice-yearly dosing in wet AMD –

Excerpt from the Press Release:

BERKELEY, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) — Valitor, a biotechnology company engineering better medicines to conquer drug limitations, today announced that its president and chief scientific officer, Wesley Jackson, Ph.D., will present at the Ophthalmology Innovation Source (OIS) XII Summit in San Diego, CA on December 3, 2022.

The presentation will review VLTR-557, an anti-VEGF therapy that is expected to provide effective therapy against wet age-related macular degeneration (AMD) with twice-yearly dosing based on preclinical findings. With VLTR-557, multiple copies of specially-engineered single-domain VHH antibodies are covalently conjugated to a hyaluronic acid biopolymer to create an anti-VEGF therapy that is long-acting, transparent – creating no optical interference, and is dosed with a standard intravitreal injection. Preclinical studies have demonstrated that VLTR-557 has an exceptional overall safety profile and does not leave residual depot materials within the eye. VLTR-557 was created using the company’s Multivalent Polymer (MVP) technology platform, which enables the development of novel macromolecular compounds through the use of biopolymers that can be engineered with multiple copies of bioactive molecules.   

“We believe we have cracked the code to making durable biologics, and our lead product candidate VLTR-557 is a prime example of the durability, potency and safety profile that is possible with our approach to drug engineering,” said Dr. Jackson.

Click the button below to read the entire Press Release:

Continue Reading The Press Release